Metformin and cancer risk
Pro Research Analysisby 
Searched over 200M research papers
Metformin and Overall Cancer Risk in Diabetic Patients
Multiple large-scale meta-analyses and systematic reviews have found that metformin use in people with type 2 diabetes is associated with a lower risk of developing cancer compared to those not using metformin or using other antidiabetic drugs. The reduction in overall cancer risk ranges from about 30% to 45% in various studies, with pooled risk ratios and odds ratios consistently below 1.0, indicating a protective effect Decensi2010O’Connor2024Noto2012+4 MORE. This association has been observed in both cohort and case-control studies, as well as in analyses comparing metformin to other diabetes medications Decensi2010O’Connor2024Noto2012+3 MORE.
Metformin and Site-Specific Cancer Risk
Gastrointestinal, Liver, and Pancreatic Cancers
The strongest evidence for a protective effect of metformin is seen in gastrointestinal cancers, especially colorectal, liver (hepatocellular), and pancreatic cancers. Studies report significant reductions in risk for these cancer types, with some analyses showing up to 80% lower risk for hepatocellular cancer and substantial reductions for colorectal and pancreatic cancers Decensi2010O’Connor2024Noto2012+3 MORE.
Breast and Urologic Cancers
The evidence for breast cancer risk reduction is mixed. Some studies show a modest decrease in risk, while others find no significant association Decensi2010O’Connor2024Franciosi2013+3 MORE. Recent genetic analyses suggest a possible protective effect specifically for HER-positive breast cancer, potentially mediated by hormonal changes . For urologic cancers, a small but significant reduction in risk has been observed .
Other Cancer Types
For other cancers such as lung, stomach, esophagus, and hematologic cancers, some studies report modest reductions in risk, but the evidence is less consistent and often not statistically significant O’Connor2024Noto2012Franciosi2013+1 MORE. There is little to no evidence that metformin reduces the risk of prostate, ovarian, uterus, bladder, kidney cancers, or melanoma Franciosi2013Soranna2012.
Cancer Mortality and Metformin Use
Several studies also report that metformin use is associated with lower cancer-related mortality among diabetic patients, with reductions in cancer death risk similar to those seen for cancer incidence Noto2012Franciosi2013.
Limitations and Potential Biases
While the association between metformin use and reduced cancer risk is strong in observational studies, these findings are subject to several important limitations. Many studies may be affected by time-related biases, such as immortal time bias, which can exaggerate the apparent benefits of metformin . Some analyses that properly account for these biases report no significant effect of metformin on cancer incidence . Additionally, publication bias and high heterogeneity among studies limit the certainty of the results O’Connor2024Soranna2012.
Need for Randomized Controlled Trials
Most of the current evidence comes from observational studies, which cannot prove causation. Randomized controlled trials specifically designed to test metformin’s effect on cancer risk and mortality are needed to confirm these findings and determine whether metformin should be used for cancer prevention in diabetic or non-diabetic populations Decensi2010O’Connor2024Noto2012+2 MORE.
Conclusion
Metformin use in people with type 2 diabetes is consistently associated with a lower risk of developing several types of cancer, especially gastrointestinal, liver, and pancreatic cancers. The evidence for other cancer types is less clear. However, the results are mainly from observational studies, which may be affected by bias. More rigorous randomized trials are needed to confirm whether metformin truly reduces cancer risk and to clarify its potential role in cancer prevention.
Sources and full results
Most relevant research papers on this topic